Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

Pfizer

Status: Completed

Conditions: Non-Melanoma Skin Carcinoma

Treatments: Other: no voriconazole (Vfend); Drug: voriconazole (Vfend)

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01480219

A1501098

Details and patient eligibility

About

The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung transplant and were continuously enrolled in a large U.S. commercial health plan.

Full description

N/A. All patients aged 18 or older who received a lung or heart/lung transplant from January 1, 2002 through December 31, 2009 in the MarketScan database were sampled.

Enrollment: 467 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 18 or older who received a lung or heart/lung transplant from January 1, 2002 through December 31, 2009 in the MarketScan database will be initially included in the study.

Exclusion criteria

• Patients who are younger than 18 years of age and who are not enrolled for at least 180 days before and 180 days after the date of transplant will be excluded.

Trial design

467 participants in 2 patient groups

Any Voriconazole

Treatment:

Drug: voriconazole (Vfend)

No Voriconazole

Treatment:

Other: no voriconazole (Vfend)